publication . Article . Other literature type . 2016

An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.

Ester Pagano; Raffaele Capasso; Fabiana Piscitelli; Barbara Romano; Olga A. Parisi; Stefania Finizio; Anna Lauritano; Vincenzo Di Marzo; Angelo A. Izzo; Francesca Borrelli;
Open Access English
  • Published: 04 Oct 2016
  • Country: Italy
Abstract
Anecdotal and scientific evidence suggests that Cannabis use may be beneficial in inflammatory bowel disease (IBD) patients. Here, we have investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS for “CBD botanical drug substance,” on mucosal inflammation and hypermotility in mouse models of intestinal inflammation. Colitis was induced in mice by intracolonic administration of dinitrobenzenesulfonic acid (DNBS). Motility was evaluated in the experimental model of intestinal hypermotility induced by irritant croton oil. CBD BDS or pure CBD were given - either intraperitoneally or by oral gavage –...
Persistent Identifiers
Subjects
Medical Subject Headings: digestive system diseasesdigestive systemsurgical procedures, operative
free text keywords: Cannabis sativa; cannabidiol; cannabinoids; colitis; inflammatory bowel disease; intestinal motility, Cannabidiol, Cannabinoids, Colitis, inflammatory bowel disease, intestinal motility, Cannabis sativa, Pharmacology, Pharmacology (medical), Original Research, lcsh:Therapeutics. Pharmacology, lcsh:RM1-950, Medicine, business.industry, business, Motility, medicine.drug, medicine.disease, Croton oil, Inflammation, medicine.symptom, Cannabis, biology.organism_classification, biology, Intracolonic
58 references, page 1 of 4

Ananthakrishnan A. N. (2015). Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 12 205–217. 10.1038/nrgastro.2015.34 [OpenAIRE] [DOI]

Aviello G. Romano B. Izzo A. A. (2008). Cannabinoids and gastrointestinal motility: animal and hu man studies. Eur. Rev. Med. Pharmacol. Sci. 12(Suppl. 1), 81–89.

Borrelli F. Aviello G. Romano B. Orlando P. Capasso R. Maiello F. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J. Mol. Med. 87 1111–1121. 10.1007/s00109-009-0512-x [OpenAIRE] [DOI]

Borrelli F. Fasolino I. Romano B. Capasso R. Maiello F. Coppola D. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 85 1306–1316. 10.1016/j.bcp.2013.01.017 [OpenAIRE] [DOI]

Borrelli F. Romano B. Petrosino S. Pagano E. Capasso R. Coppola D. (2015). Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br. J. Pharmacol. 172 142–158. 10.1111/bph.12907 [OpenAIRE] [DOI]

Brierley S. M. Linden D. R. (2014). Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat. Rev. Gastroenterol. Hepatol. 11 611–627. 10.1038/nrgastro.2014.103 [OpenAIRE] [DOI]

Brodie J. S. Di Marzo V. Guy G. W. (2015). Polypharmacology shakes hands with complex aetiopathology. Trends Pharmacol. Sci. 36 802–821. 10.1016/j.tips.2015.08.010 [OpenAIRE] [DOI]

Burstein S. (2015). Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg. Med. Chem. 23 1377–1385. 10.1016/j.bmc.2015.01.059 [OpenAIRE] [DOI]

Campos A. C. Moreira F. A. Gomes F. V. Del Bel E. A. Guimarães F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 3364–3378. 10.1098/rstb.2011.0389 [OpenAIRE] [DOI]

Capasso R. Borrelli F. Aviello G. Romano B. Scalisi C. Capasso F. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br. J. Phar macol. 154 1001–1008. 10.1038/bjp.2008.177 [OpenAIRE] [DOI]

Capasso R. Orlando P. Pagano E. Aveta T. Buono L. Borrelli F. (2014). Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 channels. Br. J. Pharmacol. 171 4026–4037. 10.1111/bph.12759 [OpenAIRE] [DOI]

Corsetti M. Tack J. (2015). Naloxegol, a new drug for the treatment of opioid-induced constipation. Expert Opin. Pharmacother. 16 399–406. 10.1517/14656566.2015.991306 [OpenAIRE] [DOI]

Curtis M. J. Bond R. A. Spina D. Ahluwalia A. Alexander S. P. Giembycz M. A. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br. J. Pharmacol. 172 3461–3471. 10.1111/bph.12856 [OpenAIRE] [DOI]

de Meijer E. P. Bagatta M. Carboni A. Crucitti P. Moliterni V. M. Ranalli P. (2003). The inheritance of chemical phenotype in Cannabis sativa L. Genetics 163 335–346. [OpenAIRE]

De Petrocellis L. Ligresti A. Moriello A. S. Allarà M. Bisogno T. Petrosino S. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 163 1479–1494. 10.1111/j.1476-5381.2010.01166.x [OpenAIRE] [DOI]

58 references, page 1 of 4
Abstract
Anecdotal and scientific evidence suggests that Cannabis use may be beneficial in inflammatory bowel disease (IBD) patients. Here, we have investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS for “CBD botanical drug substance,” on mucosal inflammation and hypermotility in mouse models of intestinal inflammation. Colitis was induced in mice by intracolonic administration of dinitrobenzenesulfonic acid (DNBS). Motility was evaluated in the experimental model of intestinal hypermotility induced by irritant croton oil. CBD BDS or pure CBD were given - either intraperitoneally or by oral gavage –...
Persistent Identifiers
Subjects
Medical Subject Headings: digestive system diseasesdigestive systemsurgical procedures, operative
free text keywords: Cannabis sativa; cannabidiol; cannabinoids; colitis; inflammatory bowel disease; intestinal motility, Cannabidiol, Cannabinoids, Colitis, inflammatory bowel disease, intestinal motility, Cannabis sativa, Pharmacology, Pharmacology (medical), Original Research, lcsh:Therapeutics. Pharmacology, lcsh:RM1-950, Medicine, business.industry, business, Motility, medicine.drug, medicine.disease, Croton oil, Inflammation, medicine.symptom, Cannabis, biology.organism_classification, biology, Intracolonic
58 references, page 1 of 4

Ananthakrishnan A. N. (2015). Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 12 205–217. 10.1038/nrgastro.2015.34 [OpenAIRE] [DOI]

Aviello G. Romano B. Izzo A. A. (2008). Cannabinoids and gastrointestinal motility: animal and hu man studies. Eur. Rev. Med. Pharmacol. Sci. 12(Suppl. 1), 81–89.

Borrelli F. Aviello G. Romano B. Orlando P. Capasso R. Maiello F. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J. Mol. Med. 87 1111–1121. 10.1007/s00109-009-0512-x [OpenAIRE] [DOI]

Borrelli F. Fasolino I. Romano B. Capasso R. Maiello F. Coppola D. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 85 1306–1316. 10.1016/j.bcp.2013.01.017 [OpenAIRE] [DOI]

Borrelli F. Romano B. Petrosino S. Pagano E. Capasso R. Coppola D. (2015). Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br. J. Pharmacol. 172 142–158. 10.1111/bph.12907 [OpenAIRE] [DOI]

Brierley S. M. Linden D. R. (2014). Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat. Rev. Gastroenterol. Hepatol. 11 611–627. 10.1038/nrgastro.2014.103 [OpenAIRE] [DOI]

Brodie J. S. Di Marzo V. Guy G. W. (2015). Polypharmacology shakes hands with complex aetiopathology. Trends Pharmacol. Sci. 36 802–821. 10.1016/j.tips.2015.08.010 [OpenAIRE] [DOI]

Burstein S. (2015). Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg. Med. Chem. 23 1377–1385. 10.1016/j.bmc.2015.01.059 [OpenAIRE] [DOI]

Campos A. C. Moreira F. A. Gomes F. V. Del Bel E. A. Guimarães F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 3364–3378. 10.1098/rstb.2011.0389 [OpenAIRE] [DOI]

Capasso R. Borrelli F. Aviello G. Romano B. Scalisi C. Capasso F. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br. J. Phar macol. 154 1001–1008. 10.1038/bjp.2008.177 [OpenAIRE] [DOI]

Capasso R. Orlando P. Pagano E. Aveta T. Buono L. Borrelli F. (2014). Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 channels. Br. J. Pharmacol. 171 4026–4037. 10.1111/bph.12759 [OpenAIRE] [DOI]

Corsetti M. Tack J. (2015). Naloxegol, a new drug for the treatment of opioid-induced constipation. Expert Opin. Pharmacother. 16 399–406. 10.1517/14656566.2015.991306 [OpenAIRE] [DOI]

Curtis M. J. Bond R. A. Spina D. Ahluwalia A. Alexander S. P. Giembycz M. A. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br. J. Pharmacol. 172 3461–3471. 10.1111/bph.12856 [OpenAIRE] [DOI]

de Meijer E. P. Bagatta M. Carboni A. Crucitti P. Moliterni V. M. Ranalli P. (2003). The inheritance of chemical phenotype in Cannabis sativa L. Genetics 163 335–346. [OpenAIRE]

De Petrocellis L. Ligresti A. Moriello A. S. Allarà M. Bisogno T. Petrosino S. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 163 1479–1494. 10.1111/j.1476-5381.2010.01166.x [OpenAIRE] [DOI]

58 references, page 1 of 4
Any information missing or wrong?Report an Issue